NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to ...

Denali Therapeutics, Inc. (NASDAQ:DNLI) shares traded higher on Wednesday after the company initiated its biologics license application (BLA) for the accelerated approval of Tividenofusp Alfa for the ...

Defence Czar rules out any talks with BLA due to its involvement in terrorist activities, killing of innocent ...

The FDA is expected to decide on treatments for COPD, psoriasis, rare neuroendocrine tumors, and a next-generation COVID-19 vaccine.

After some high-profile crashes, the one-time biotech darling is inching toward success with its Hunter syndrome treatment, ...

Denali Therapeutics (DNLI) announced that the company’s initiation of a rolling submission of a biologics license application, BLA, for ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Recently, the National Medical Products Administration (NMPA) issued the draft version of 'Implementation Measures for Drug Trial Data ...

Cellares' forward momentum continues, as the company announced April 1, 2025, a notable milestone for its Cell Shuttle.

The FDA has accepted for Priority Review the BLA for apitegromab for the improvement of motor function in patients with spinal muscular atrophy.

Q4 2024 Earnings Call Transcript March 31, 2025 Omeros Corporation beats earnings expectations. Reported EPS is $-0.54, ...

A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of ...